Dissertation > Excellent graduate degree dissertation topics show

The Effect of Chemotherapy on Treg in Peripheral Blood of Patients with Breast Cancer

Author: LuXiaoZuo
Tutor: LiuJunTian；LiHui；LiuJun
School: Tianjin Medical University
Course: Oncology
Keywords: Breast Cancer Chemotherapy Docetaxel CD4 CD25 regulatory T cells Cytokines
CLC: R737.9
Type: Master's thesis
Year: 2008
Downloads: 71
Quote: 0
Read: Download Dissertation

Abstract


Purpose Treg (CD 4 CD 25 regulatory T cells) can inhibit the proliferation of T cells and NK cells and activation, prevent autoimmune disease has an important role in maintaining the stability of the immune system; However, in recent years, studies have shown that Treg cells play an important role in tumor immunosuppression same. This research aims to study the impact and significance of Treg cells in the peripheral blood after chemotherapy drugs to cure breast cancer patients, and provide useful information for the comprehensive treatment of breast cancer. Method collected 52 cases of peripheral venous blood before the chemotherapy of breast cancer patients after one day and 10 days after chemotherapy, 52 patients with breast cancer were treated with TE program (docetaxel and epirubicin) chemotherapy, patients with pathological type by pathological are invasive ductal carcinoma of the histological diagnosis. The application flow cytometry in peripheral blood Treg cells as well as CD 3 CD 4 CD 8 T cells accounted for the percentage of T lymphocytes, using IL-4 in the peripheral blood of the ELLSA assay, the expression levels of IL-10, TGF-β1 and IFN-γ. Breast cancer patients after chemotherapy total percentage of T lymphocytes in peripheral blood Treg cells (4.75 ± 1.60)% compared with chemotherapy (5.59 ± 1.81)% reduce (P <0.05), and the the Treg cells change with the patient's age, lymph nodes with or without transfer, number of lymph node metastasis, and independent of menopausal status (P> 0.05). Before and after chemotherapy CD 3 cells accounted for the proportion of T lymphocytes (64.690 ± 7.469)%, (64.357 ± 9.356)% (P> 0.05). Before and after chemotherapy CD 4 T cells accounted for the proportion of T lymphocytes (38.048 ± 10.671)%, (36.536 ± 9.664)% (P> 0.05). After chemotherapy CD 8 T cells in T lymphocyte ratio (28.129 ± 10.900) (24.876 ± 6.631)%% compared with chemotherapy increased (P <0.05). After chemotherapy CD 4 / CD 8 (1.506 ± 0.691) (1.680 ± 0.704) than before chemotherapy reduce ( P <0.05). The four chemotherapy before and after the change and CD of Treg cells 3 the T cellular changes, and CD 4 / CD 8 was no correlation (P> 0.05). Peripheral blood of breast cancer patients after chemotherapy in IL-4, IL-10, TGF-β1 concentration than before chemotherapy reduce IFN-γ concentration increased (P <0.05). Changes in Treg cells and the cytokines IL-4, IL-10, TGF-β1 and IFN-γ concentration before and after chemotherapy was no significant correlation (P> 0.05). Conclusion Chemotherapy proportion of T lymphocytes of the peripheral blood Treg cells accounted reduce CD 8 increase in the proportion of T lymphocyte subsets, help to improve cancer treatment, breast cancer patients can be effect. Changes in the peripheral blood of breast cancer patients in the soluble cytokine IL-4, IL-10, TGF-β1 and IFN-γ concentration after chemotherapy, but can not yet prove that Treg cells by more than play an inhibitory cytokine in tumor immunity.

Related Dissertations

  1. Study of Sepia Ink-Astragalus Preparation for Relieving Damage Caused by Chemotherapy,R285.5
  2. Yu Ren- Cun Academic Thought and clinical experience in the clinical observation of combination chemotherapy in advanced gastric cancer with Yiqihuoxuejiedu side,R249
  3. The Influence in Different Route of Medication with Vitamin A on CD4~+CD25~+ Regulatory T Cell and Cell Factor of IL-4、 IFN-γ in a Rat Persistent Asthma Model,R562.25
  4. Inhibition of Conventional Chemotherapy Combined with Metronomic Chemotherapy on Breast Cancer Xenografts in Nude Mice,R737.9
  5. Comparative Analysis on CTF and CEF Regimens as Postoperative Adjuvant Chemotherapy in the Treatment of Phase Ⅱ Breast Cancer,R737.9
  6. Effects on Telomere Length of Epithelial Ovarian Cancer by Chemotherapy,R737.31
  7. Recurrent Ovarian Cancer Surgery Again with Surial Analysis of Relevant Factors,R737.31
  8. Clinical Observation of Pemetrexed for Treating Advanced Non-small Cell Lung Cancer,R734.2
  9. The Experimental Study of Antiangiogenic and Induction of Apoptosis by Maximum Tolerated Dose Combined with Low-dose Cyclophosphamide in Breast Cancer,R737.9
  10. Maximum Tolerated Dose Combined with Metronomic Chemoterpy on Proliferation and Angiogenesis in Treatment of Breast Cancer,R737.9
  11. The Shrink Pattern of Breast Cancer After Neoadjuvant Chemotherapy and the Correlation with Partial Clinic Pathological Factors: Preliminary Results of a Plot Study,R737.9
  12. The Relationship between CEF/TE Neo-adjuvant Chemotherapy, MAPK/PI3K Signal Pathway and Ki-67 in Breast Cancer,R737.9
  13. The Protective Effects of Glucagon-like Peptide -2 on Intestinal Barrier Function of Doxorubicin Chemotherapy in Rats,R730.5
  14. Effect of the Function of MRP1 on Human Lung Adenocarcinoma Chemotherapy Resistance,R734.2
  15. The Effect and Significance of Combination Chemotherapy in the Expression of CD90 and CD44 in Human Hepatoma Cell Line HepG2,R735.7
  16. The Expression and Clinical Significance of Ercc1 in Human Gastric Cancer,R735.2
  17. Clinical Characteristics and Prognosis Analysis of Advanced Cholan Giocarcinoma,R735.8
  18. Expression and Prognostic Significance of TS and BRCAl mRNA in Non-small Cell Lung Cancer,R734.2
  19. Clinical Study on Effect of Xie Shi Lung Cancer NO.2 in Malignant Pleural Effusion of Lung Cancer,R734.2
  20. Glioma resistance related gene expression and its clinical significance,R739.4
  21. Low- dose cisplatin liver cancer stem cells enriched experimental study,R735.7

CLC: > Medicine, health > Oncology > Genitourinary tumors > Breast tumor
© 2012 www.DissertationTopic.Net  Mobile